GH Research Plc
February 03, 2025 - by Joey Ramson
$GHRS shares are surging today and leading the Prism MarketView Psychedelics index after they released results from their Phase 2b trial for GH001, aimed at treating treatment-resistant depression (TRD), successfully met its primary endpoint.
